Publicaciones
-
Sampor C, Alonso R, Durañona M, Gorostegui M, Antillón-Klussmann F, Lopes LF, Cappellano AM, Gonzalez-Ramella O, Lobos P, Palma J, Grynszpancholc E, Vasquez L, Morales-La Madrid A, Moreira DC, Cruz-Martínez O and Chantada G.
The TeLeo Program: Tele-education in pediatric oncology as a tool to support training programs in Latin America.
PEDIATRIC BLOOD & CANCER . 71(12): .
-
Fufa D, Mdoka C, Ayalew M, Khofi H, Amankwah E, Chokwenda N, Mezgebu E, Mavinkurve-Groothuis AMC, Kamiza S, Chikaphonya-Phiri B, Wassie M, Atwiine B, Branchard M, Gorostegui M, Parkes J, Kudowa E, Eklu B, Jator B, Renner LA, Borgstein E, Molyneux E, Kouya F, Pritchard-Jones K, Paintsil V, Chitsike I, Chagaluka G and Israels T.
Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub-Saharan Africa: A report from Wilms Africa Phase II-CANCaRe Africa.
PEDIATRIC BLOOD & CANCER . 71(11): .
-
Krauel L, Pasten A, Gorostegui M, Mañé S, Martin Giménez MP, Coronas-Soucheiron M, Carrasco-Torrents R and Mora J.
Use of Radioguided Surgery for Small and Difficult-to-Locate Relapsed MIBG (+) High-Risk Neuroblastoma Lesions.
Cancers . 16(19): .
-
Cappellano A, Gorostegui M, Gonzalez-Ramella O, Filho NPC, Valencia D, Chantada L, Sampor C, Serrano MJ, Macedo C, Ramirez O, Sardinas S, Lezcano E, Calderón P, Gamboa Y, Fu L, Gómez W, Schelotto M, Ugaz C, Lobos P, Aguiar SDS, Moreno K, Palma J, Sánchez G, Moschella F, Gassant PYH, Velasquez T, Quintero K, Moreno F, Villarroel M, Fuentes Alabi S, Vasquez L, Challinor J and Chantada G.
International Society of Paediatric Oncology (SIOP) Global Mapping Programme: Latin American Society of Pediatric Oncology (SLAOP) country-level report
PEDIATRIC BLOOD & CANCER . 71(6): . Nº de citas: 2
-
Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.
Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects.
Frontiers in oncology . 14: 1380917-1380917.
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Nº de citas: 1
-
Chantada L, Gorostegui M, Lowe J, Ranasinghe N, Villegas L, Geel J, Howard S, Bouffet E, Chantada G, Challinor J and Cappellano A.
SIOP pediatric oncology services Global Mapping Program: Latin American data collection
PEDIATRIC BLOOD & CANCER . 71(2): . Nº de citas: 2
-
Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
Cancers . 15(19): . Nº de citas: 7
-
Varo A, Castañeda-Heredia A, Chamorro S, Muñoz JP, Gorostegui M, Celma MS, Lopez S, Simao M, Pérez-Jaume S and Mora J.
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
Frontiers in oncology . 13: 1164949-1164949. Nº de citas: 4
-
Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report
Cancers . 15(9): . Nº de citas: 7